Publications by authors named "Michael A Nauck"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

236,879

Total Likes

7,197

Extended Reach

2,971,554

Social Features

624
C
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Stephen J Nicholls, Deepak L Bhatt, John B Buse, Stefano Del Prato, Steven E Kahn, A Michael Lincoff, Darren K McGuire, Michael A Nauck, Steven E Nissen, Naveed Sattar

Am Heart J· January 2024

Videos about Article: user user

2 1 47 2 11

View All Article and Social Media Activity
T
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Michael A Nauck, David A D'Alessio

September 2022

Videos about Article: user user

2 44 11

View All Article and Social Media Activity
C
Consensus report: definition and interpretation of remission in type 2 diabetes.
Matthew C Riddle, William T Cefalu, Philip H Evans, Hertzel C Gerstein, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip Schauer

Diabetologia· November 2021

Videos about Article: user user user

3 6 205 9

View All Article and Social Media Activity
C
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.
Matthew C Riddle, William T Cefalu, Philip H Evans, Hertzel C Gerstein, Michael A Nauck, William K Oh, Amy E Rothberg, Carel W le Roux, Francesco Rubino, Philip Schauer

August 2021

Videos about Article: user user user 1

4 4 293 11 47

View All Article and Social Media Activity
G
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier

April 2021

Videos about Article: user user user 3

6 1 2 12 3 114

View All Article and Social Media Activity
L
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn

July 2016

Videos about Article: user user user

3 1 46 17 140

View All Article and Social Media Activity
C
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Stephen J Nicholls, Imre Pavo, Deepak L Bhatt, John B Buse, Stefano Del Prato, Michael A Nauck

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity.
Jang Won Son, Carel W le Roux, Matthias Blüher, Michael A Nauck, Soo Lim

Endocr Rev· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
Yu Mi Kang, Viktoria Punov, Soo Lim, Michael A Nauck

Diabetes Obes Metab· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose-dependent insulinotropic polypeptide (GIP).
Timo D Müller, Alice Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas L Birkenfeld, Michael A Nauck

Mol Metab· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promising treatment options with tirzepatide for Japanese individuals with obesity disease.
Michael A Nauck, Soo Lim

Lancet Diabetes Endocrinol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4.
Michael A Nauck, Waldemar Uhl

J Clin Endocrinol Metab· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study.
Daniel R Quast, Cong Xie, Michelle J Bound, Jacqueline Grivell, Seva Hatzinikolas, Michael A Nauck

Diabetes· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes.
Hun Jee Choe, Michael A Nauck, Joon Ho Moon

Endocrinol Metab (Seoul)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
Ryan J Jalleh, Mark P Plummer, Chinmay S Marathe, Mahesh M Umapathysivam, Daniel R Quast, Michael A Nauck

J Clin Endocrinol Metab· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcome with SGLT2i and GLP1RA.
Soo Lim, Minji Sohn, Michael A Nauck

Eur J Intern Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility.
Ryan J Jalleh, Chinmay S Marathe, Christopher K Rayner, Karen L Jones, Mahesh M Umapathysivam, Michael A Nauck

Endocrinology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.
Daniel R Quast, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Michael A Nauck

Diabetes Obes Metab· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of Type 2 Diabetes.
Rüdiger Landgraf, Jens Aberle, Andreas L Birkenfeld, Baptist Gallwitz, Monika Kellerer, Michael A Nauck

Exp Clin Endocrinol Diabetes· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
Minji Sohn, Seoungyeon Nam, Michael A Nauck, Soo Lim

BMC Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.
Thomas Karagiannis, Apostolos Tsapas, Eleni Bekiari, Konstantinos A Toulis, Michael A Nauck

Diabetes Care· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incretin hormones and type 2 diabetes.
Michael A Nauck, Timo D Müller

Diabetologia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective External Validation of an Algorithm Predicting Hourly Basal Insulin Infusion Rates from Characteristics of Patients with Type 1 Diabetes Treated with Insulin Pumps.
Jana S Schmelzer, Melanie Kahle-Stephan, Juris J Meier, Michael A Nauck

Exp Clin Endocrinol Diabetes· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.
Michael A Nauck, Michael Horowitz

Lancet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis.
Dominik Wollenhaupt, Jannik Wolters, Mirna Abd El Aziz, Michael A Nauck

BMJ Open Diabetes Res Care· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
Ruben Nogueiras, Michael A Nauck, Matthias H Tschöp

Nat Metab· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Minji Sohn, Johannes W Dietrich, Michael A Nauck, Soo Lim

Cardiovasc Diabetol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Michael A Nauck, Abd El Aziz Mirna, Daniel R Quast

Diabetes Obes Metab· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
Soo Lim, Minji Sohn, Jose C Florez, Michael A Nauck, Jiyoung Ahn

Nutrients· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review.
Sebastian Birker, Juris J Meier, Michael A Nauck

Sci Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis